Education
About Us
Working with TipRanks
Follow Us
Eisai Co Ltd (JP:4523)
:4523
Top Page
Eisai Co
(OTC:4523)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥4,388.00
▼(-13.98% Downside)
Eisai Co's solid financial performance, characterized by strong balance sheet health and profitability, is the most significant factor driving the score. Technical indicators suggest limited momentum, while high valuation metrics slightly dampen the outlook. Cash flow management improvements are needed for enhanced financial flexibility.
Eisai Co (4523) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
$1.44T
Dividend Yield3.14%
Average Volume (3M)1.48M
Price to Earnings (P/E)28.6
Beta (1Y)0.87
Revenue Growth9.43%
EPS Growth56.53%
CountryJP
Employees11,067
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)51.35
Shares Outstanding291,649,140
10 Day Avg. Volume1,072,730
30 Day Avg. Volume1,484,823
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.45
Enterprise Value/Gross Profit1.85
Enterprise Value/Ebitda11.10
Forecast
1Y Price Target
$5,251.27Price Target Upside2.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Eisai Co Business Overview & Revenue Model
Company DescriptionEisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyEisai Co., Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company invests heavily in research and development to discover new drugs and enhance its existing portfolio, which includes key medications for the treatment of Alzheimer's disease, epilepsy, and various cancers. Eisai's revenue streams are bolstered by its strategic partnerships and collaborations with other pharmaceutical companies, which help to expand its market reach and leverage expertise in drug development. Additionally, Eisai benefits from global sales across major markets including Japan, the United States, Europe, and Asia. The company's earnings are further supported by licensing agreements and royalties from patented products.
Eisai Co Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q4-2025)
| Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Neutral
The earnings call presented a strong performance of their global brands and significant global expansion of LEQEMBI, contributing to positive revenue growth. However, challenges in controlling cost of sales, slower-than-expected U.S. market expansion, and concerns about competitive threats were notable downsides.Q4-2025 Updates
Positive Updates
Strong Performance of Global Brands
Three global products, LENVIMA, Lemborexant, and LEQEMBI, achieved ¥426.5 billion in revenue, with a year-over-year increase of 24%.
LEQEMBI Global Reach
LEQEMBI was approved in 44 countries and is under regulatory review in 12 countries, marking significant global expansion.
Positive Revenue Growth
The company achieved ¥789.4 billion in revenue, a 6% increase from the previous year, exceeding forecasts.
LEQEMBI Revenue Exceeded Forecast
Global LEQEMBI revenue for FY 2024 was ¥44.3 billion, exceeding the full-year forecast.
LENVIMA's Double-Digit Growth
LENVIMA achieved over ¥328 billion in global revenue with a 28% year-over-year growth in the Americas.
Negative Updates
Increased Cost of Sales
Cost of sales increased by 1.7 percentage points due to the Inflation Reduction Act related expenses for Lenvima and product mix changes.
Challenges in U.S. Market Expansion
LEQEMBI's penetration in the U.S. was slower than expected, with the market just approaching the end of the demand stimulation phase.
High R&D and SG&A Expenses
Significant resources were allocated to LEQEMBI, impacting operating profit, although R&D expenses for LEQEMBI are expected to decrease.
Concerns About Competitive Threats
Questions were raised about the competitive impact from other products like Cassella, although the company downplayed the threat.
Company Guidance
In the recent financial results briefing session for Eisai Co. Limited, the company reported exceeding its revenue and profit forecasts for fiscal year 2024, driven mainly by its global brands: LENVIMA, Lemborexant (Dayvigo), and LEQEMBI, which together achieved a year-on-year revenue increase of 24%, contributing ¥426.5 billion. LEQEMBI alone saw a substantial revenue increase of ¥40 billion. Despite a 0.5 percentage point rise in the cost of sales due to one-time revenue decreases, the company managed to reduce its R&D expenses ratio by 1.6 percentage points, largely because of the closure of inactive research laboratories. SG&A expenses increased by 1.2 percentage points due to ongoing investments in LEQEMBI's marketing, yet the company controlled these expenses within anticipated limits. Globally, LEQEMBI's revenue was reported at JPY 44.3 billion, surpassing the full-year forecast. The company also highlighted LEQEMBI's approval in 44 countries, with plans to launch in Europe, particularly Germany and Austria, in the second half of fiscal year 2025. For the upcoming fiscal year 2025, Eisai forecasts LEQEMBI's global revenue to reach ¥76.5 billion, with significant contributions expected from the United States and Japan as they enter the demand expansion phase.Eisai Co Financial Statement Overview
Summary
Eisai Co reflects a commendable financial position with solid growth and profitability. The income statement indicates steady revenue growth with some challenges in operational efficiency. The balance sheet is robust with low leverage and strong equity ratios, underscoring financial health. However, cash flow management requires attention to ensure sustainable growth.Income Statement
Eisai Co has demonstrated solid revenue growth with a notable increase from 2024 to 2025. The gross profit margin remains strong, indicating efficient cost management. However, the EBIT margin has decreased slightly, signaling potential pressure on operational efficiency. Net profit margin shows robust performance, though the decrease in EBIT suggests a need for operational improvements.75
Positive
Balance Sheet
The balance sheet is strong with a healthy equity ratio, indicating financial stability. The company maintains a low debt-to-equity ratio, suggesting prudent leverage management. Return on equity remains impressive, reflecting effective utilization of shareholder funds. Overall, the balance sheet supports the company's growth trajectory with minimal financial risk.80
Positive
Cash Flow
Eisai Co shows a mixed picture in cash flow metrics. While the operating cash flow to net income ratio is positive, free cash flow has decreased significantly, indicating challenges in cash generation. The drop in free cash flow growth is noteworthy, suggesting potential issues in funding operations or investments. Improvements in cash flow management could enhance financial flexibility.70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 789.40B | 789.40B | 741.75B | 744.40B | 756.23B | 645.94B |
| Gross Profit | 620.59B | 620.59B | 586.42B | 566.57B | 581.39B | 484.63B |
| EBITDA | 103.39B | 104.49B | 103.11B | 87.26B | 94.55B | 90.05B |
| Net Income | 46.43B | 46.43B | 42.41B | 55.43B | 47.95B | 41.94B |
Balance Sheet | ||||||
| Total Assets | 1.39T | 1.39T | 1.39T | 1.26T | 1.24T | 1.09T |
| Cash, Cash Equivalents and Short-Term Investments | 265.56B | 265.56B | 305.12B | 267.89B | 310.06B | 249.01B |
| Total Debt | 187.52B | 187.52B | 159.41B | 126.11B | 94.89B | 89.89B |
| Total Liabilities | 520.58B | 520.58B | 494.82B | 440.78B | 467.78B | 362.07B |
| Stockholders Equity | 841.42B | 841.42B | 875.61B | 799.96B | 748.82B | 703.18B |
Cash Flow | ||||||
| Free Cash Flow | 18.18B | 18.18B | 31.17B | -36.33B | 77.12B | 35.71B |
| Operating Cash Flow | 30.12B | 30.12B | 55.99B | -1.77B | 117.59B | 73.85B |
| Investing Cash Flow | -10.10B | -10.10B | -25.32B | -22.72B | -28.85B | -36.87B |
| Financing Cash Flow | -57.81B | -57.81B | -22.72B | -24.52B | -48.97B | -55.91B |
Eisai Co Technical Analysis
Positive
5101.00
Price Trends
4630.92
Positive
4314.59
Positive
4260.28
Positive
Market Momentum
155.81
Positive
58.08
Neutral
41.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4523, the sentiment is Positive. The current price of 5101 is above the 20-day moving average (MA) of 5049.85, above the 50-day MA of 4630.92, and above the 200-day MA of 4260.28, indicating a bullish trend. The MACD of 155.81 indicates Positive momentum. The RSI at 58.08 is Neutral, neither overbought nor oversold. The STOCH value of 41.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4523.
Eisai Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ¥2.32T | 12.53 | 12.51% | 2.17% | 4.04% | 21.20% | |
76 Outperform | ¥303.89B | 15.57 | 7.86% | 2.52% | 6.49% | 38.42% | |
74 Outperform | ¥283.23B | 10.95 | 10.79% | 3.67% | 14.60% | 8.97% | |
67 Neutral | $1.44T | 28.62 | 5.96% | 3.14% | 9.43% | 56.53% | |
65 Neutral | ¥7.03T | 50.90 | 1.99% | 4.42% | 1.52% | -8.68% | |
63 Neutral | ¥632.89B | 33.48 | 10.73% | ― | 26.28% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4523
Eisai Co
5,101.00
-146.15
-2.79%
DNPUF
Sumitomo Dainippon Pharma Co
11.58
7.46
181.07%
HTSUF
Hisamitsu Pharmaceutical Co
27.90
1.54
5.84%
SGIOF
Shionogi & Co
19.00
5.09
36.59%
TKPHF
Takeda Pharmaceutical Co
29.40
1.22
4.33%
TSMRF
Tsumura & Co
24.20
-6.97
-22.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.